Celltrion’s Remsima occupies 40% of original drug market in Europe

The number of European patients who were prescribed the Celltrion’s biosimilar antibody Remsima was observed to exceed approximately 105 thousand people as of the 2^nd quarter this year.

According to Celltrion, Remsima recorded collective 58 thousand patients in the end of the last year, 82 thousand in the 1^st quarter of 2016, and 105 thousand patients at the end of 2^nd quarter as having additi...